| Study Period | 2021 - 2030 |
| Market Size (2025) | USD 3.90 Billion |
| Market Size (2030) | USD 6.63 Billion |
| CAGR (2025 - 2030) | 11.18 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Vaccine Contract Manufacturing Market Analysis
The Vaccine Contract Manufacturing Market size is estimated at USD 3.90 billion in 2025, and is expected to reach USD 6.63 billion by 2030, at a CAGR of 11.18% during the forecast period (2025-2030).
The vaccine contract manufacturing industry is experiencing significant transformation driven by technological innovation and increasing manufacturing complexity. Contract manufacturers are increasingly adopting advanced technologies such as artificial intelligence, machine learning, and cloud-based platforms to optimize production processes and enhance efficiency. The integration of product lifecycle management systems with sophisticated control systems like Emerson's DeltaV Distributed Control System (DCS) and Syncade Manufacturing Execution System (MES) is enabling more flexible and scalable manufacturing processes. This digital transformation is particularly evident in data management and process control, allowing manufacturers to rapidly adjust and optimize production parameters.
The industry is witnessing substantial investments in manufacturing infrastructure and capacity expansion. In November 2022, ReiThera, an Italian biotech and contract manufacturing company, invested EUR 15 million in expanding its facilities, focusing on large-scale viral vectors for vaccines and gene therapies. This trend of facility expansion is complemented by strategic partnerships, as exemplified by Bavarian Nordic's collaboration with Grand River Aseptic Manufacturing (GRAM) in 2022 for the fill and finish of vaccines, demonstrating the industry's commitment to enhancing production capabilities and meeting growing demand in the vaccine contract manufacturing market.
The market is characterized by increasing specialization and diversification of services offered by contract manufacturers. Contract Development and Manufacturing Organizations (CDMOs) are expanding their service portfolios to include specialized capabilities such as mRNA vaccine manufacturing, cell and gene therapy manufacturing, and advanced analytical services. This trend is reflected in the growing number of active CDMO relationships, with leading companies like Emergent Biosolutions maintaining over 60 active CDMO customers, indicating the industry's robust client base and diverse service requirements.
The industry is experiencing a shift towards more flexible and modular manufacturing approaches. Manufacturers are increasingly adopting single-use technologies, automated processing systems, and prefabricated, self-contained modular bioprocessing units. This evolution is supported by significant international investment, as evidenced by the ACT-Accelerator strategy's call for USD 23.4 billion in international investment to address global vaccine manufacturing disparities. These developments are accompanied by a growing focus on sustainability and cost-effectiveness in manufacturing processes, with companies implementing energy-efficient technologies and optimizing resource utilization throughout the production cycle. The focus on sustainability is becoming a critical component of vaccine development and manufacturing strategies.
Vaccine Contract Manufacturing Market Trends
Advancements in Technology, Cost Benefits in Infrastructure, and Operational Benefits
The vaccine contract manufacturing industry is experiencing significant transformation through rapid advancements in genetic engineering, vaccine delivery technology, and proteomics. These technological developments have revolutionized the understanding of host-pathogen interaction and immune response regulation, opening unlimited possibilities for new immunization strategies. The implementation of advanced technologies like recombinant microorganisms, bacterial or viral vectors, synthetic peptides, and natural and synthetic polysaccharides has enabled manufacturers to develop more efficient and cost-effective production processes. Additionally, the integration of automation, monitoring, and process control systems, including prefabricated modular bioprocessing units and single-use technologies, has significantly reduced operational costs while maintaining high-quality standards.
The adoption of innovative manufacturing solutions has demonstrated substantial cost benefits in infrastructure and operations. For instance, contract manufacturing eliminates the need for dedicated in-house resources and helps avoid unexpected costs associated with vendor management. The implementation of modern manufacturing solutions, such as virus implantation technology and continuous cell lines, has improved production efficiency while reducing labor costs significantly. Furthermore, the industry has witnessed the emergence of automated processing with software integration, leading to enhanced quality control and reduced human error in viral vaccine manufacturing, ultimately resulting in more consistent and reliable manufacturing processes.
Understand The Key Trends Shaping This Market
Download PDF
Increase in Initiatives Favoring Vaccinations
Global health organizations and governments worldwide have significantly increased their support for vaccination programs through various initiatives and funding mechanisms. The establishment of comprehensive immunization programs and awareness campaigns has created a strong foundation for sustained vaccine demand. For instance, in 2022, the Government of Canada implemented the Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine, authorizing new recombinant quadrivalent seasonal influenza vaccines for adults. These initiatives have been complemented by substantial funding commitments, exemplified by the United States' allocation of USD 253 million in 2022 for polio eradication efforts as part of the Global Polio Eradication Initiative.
The industry has witnessed a surge in public-private partnerships and international collaborations aimed at scaling up vaccine development and manufacturing capabilities. Health organizations have launched numerous awareness campaigns and vaccination drives to increase immunization rates across different age groups. These initiatives have been supported by regulatory bodies through streamlined approval processes and enhanced safety monitoring systems. The implementation of mobile vaccination programs and targeted outreach efforts has further contributed to increased vaccine accessibility and uptake, creating a sustained demand for vaccine manufacturing services.
Favorable Patient Demographics and Growing Vaccinations of Newborns and Children
The increasing focus on early-life immunization has emerged as a crucial driver for the vaccine contract manufacturing market. According to the American Academy of Pediatrics data from 2022, the critical nature of early vaccination is emphasized by statistics showing that individuals infected with hepatitis B as babies have a 90% chance of developing serious chronic conditions later in life. This understanding has led to expanded vaccination programs for newborns and children, covering a comprehensive range of diseases including hepatitis A and B, rotavirus, diphtheria, tetanus, acellular pertussis, Hemophilus influenzae type b, polio, pneumococcal disease, measles, mumps, rubella, varicella, and influenza.
The growing emphasis on preventive healthcare has resulted in increased investment in pediatric vaccination programs worldwide. Healthcare providers and governments have recognized the economic and social benefits of early vaccination, leading to the implementation of more comprehensive immunization schedules for children. The expansion of vaccine coverage has been supported by improved healthcare infrastructure and delivery systems, ensuring better access to vaccination services for diverse population groups. Additionally, the development of combination vaccines and improved delivery mechanisms has enhanced the efficiency of childhood immunization programs, making it easier for healthcare providers to administer multiple vaccines while maintaining high safety standards. Furthermore, the integration of mRNA vaccine manufacturing techniques has been pivotal in advancing these pediatric programs.
Segment Analysis: By Vaccine Type
Live-attenuated Vaccines Segment in Vaccine Contract Manufacturing Market
The live-attenuated vaccines segment dominates the vaccine contract manufacturing market, holding approximately 31% market share in 2024. This segment's leadership position is attributed to the growing demand for vaccines against diseases such as measles, mumps, rubella, and chickenpox. Live-attenuated vaccines are particularly effective as they produce strong cellular and antibody responses that often confer lifelong immunity with just one or two doses. The segment's growth is further supported by ongoing research and development activities, new vaccine approvals, and the increasing adoption of these vaccines in national immunization programs worldwide. Contract manufacturers are expanding their capabilities in this segment to meet the rising demand for live-attenuated vaccines, particularly focusing on advanced manufacturing technologies and quality control measures.
RNA Vaccines Segment in Vaccine Contract Manufacturing Market
The RNA vaccines segment is emerging as the fastest-growing segment in the vaccine contract manufacturing market, with an expected growth rate of approximately 12% during 2024-2029. This remarkable growth is driven by the increasing adoption of mRNA vaccine manufacturing technology for vaccine development, particularly following the successful deployment of COVID-19 vaccines. Contract manufacturers are significantly investing in RNA vaccine production capabilities, expanding their facilities, and implementing specialized manufacturing processes. The segment's growth is further supported by ongoing research into using mRNA vaccine manufacturing technology for developing vaccines against other infectious diseases, cancer, and rare diseases. The advantages of RNA vaccines, including rapid development timelines, cost-effective manufacturing processes, and the ability to quickly modify vaccines to address new variants, are contributing to their increasing adoption in the pharmaceutical industry.
Remaining Segments in Vaccine Contract Manufacturing Market
The vaccine contract manufacturing market also encompasses inactivated vaccines, sub-unit vaccines, and toxoid-based vaccines segments, each serving distinct market needs. Inactivated vaccines continue to be crucial for diseases requiring complete virus neutralization, while sub-unit vaccines are gaining prominence due to their high safety profile and specific immune response targeting. Toxoid-based vaccines remain essential for preventing diseases caused by bacterial toxins, such as tetanus and diphtheria. These segments are witnessing steady growth driven by technological advancements in manufacturing processes, increasing investment in research and development, and growing demand for specialized vaccine formulations. Contract manufacturers are expanding their capabilities across these segments to offer comprehensive manufacturing solutions to vaccine developers.
Segment Analysis: By Process
Downstream Segment in Vaccine Contract Manufacturing Market
The downstream segment dominates the vaccine contract manufacturing market, holding approximately 80% of the market share in 2024. This significant market position is attributed to the critical role of downstream processes in ensuring vaccine quality and safety. The segment encompasses essential services such as analytical and QC studies, vaccine fill finish operations, packaging, and other crucial downstream processes. The robust market share reflects the increasing demand for sophisticated quality control measures and the growing importance of final product preparation in vaccine manufacturing. Major pharmaceutical companies and contract manufacturers are investing heavily in downstream capabilities, particularly in areas like sterile fill-finish operations and advanced analytical testing, to meet the stringent regulatory requirements and ensure product safety and efficacy.
Upstream Segment in Vaccine Contract Manufacturing Market
The upstream segment is emerging as the fastest-growing segment in the vaccine contract manufacturing market, with a projected growth rate of approximately 12% during 2024-2029. This accelerated growth is driven by technological advancements in cell culture technologies, increasing adoption of single-use systems, and the rising demand for complex biologics production. The segment's growth is further supported by innovations in bacterial, mammalian, and insect cell expression systems, which are crucial for vaccine production. Contract manufacturers are expanding their upstream processing capabilities to accommodate the growing demand for various vaccine types, including viral vaccine manufacturing, mRNA vaccines, viral vectors, and protein-based vaccines, while implementing advanced bioprocessing technologies to improve yield and efficiency.
Segment Analysis: By Scale of Operations
Clinical Segment in Vaccine Contract Manufacturing Market
The clinical segment dominates the vaccine contract manufacturing market, holding approximately 54% of the market share in 2024. This significant market position is driven by the increasing number of clinical trials and studies being conducted globally for vaccine development. The segment's growth is supported by substantial government funding and strategic partnerships between contract manufacturers and pharmaceutical companies. Clinical-stage manufacturing services are in high demand as companies focus on developing novel vaccines for emerging diseases and improving existing vaccination solutions. The segment benefits from advanced manufacturing technologies, stringent quality control measures, and the ability to scale production efficiently. Additionally, the rising investment in research and development activities and the growing pipeline of vaccine candidates in clinical trials continue to fuel the segment's dominance in the market.
Preclinical Segment in Vaccine Contract Manufacturing Market
The preclinical segment is projected to experience the fastest growth rate of approximately 11% during the forecast period 2024-2029. This accelerated growth is attributed to the increasing emphasis on early-stage vaccine development and the rising number of new vaccine candidates entering the preclinical phase. Contract manufacturers are expanding their preclinical testing capabilities to meet the growing demand for safety and efficacy studies before advancing to clinical trials. The segment is witnessing significant technological advancements in testing methodologies and increased adoption of automated systems for preclinical research. Furthermore, the rising investment in research and development activities, coupled with the growing focus on developing vaccines for emerging diseases, is driving the demand for preclinical manufacturing services. The segment also benefits from the increasing number of biotechnology startups and research institutions outsourcing their preclinical manufacturing needs.
Remaining Segments in Scale of Operations
The commercial segment represents a crucial component of the vaccine contract manufacturing market, focusing on large-scale production of approved vaccines for market distribution. This segment plays a vital role in ensuring a consistent supply of vaccines to meet global immunization needs. Commercial manufacturing services involve sophisticated production facilities, advanced quality control systems, and compliance with regulatory requirements across different regions. The segment is characterized by long-term manufacturing agreements, strategic partnerships with pharmaceutical companies, and continuous process optimization to improve production efficiency. Contract manufacturers in this segment typically offer end-to-end services, including vaccine bulk manufacturing, fill-finish operations, and packaging solutions, making them essential partners in the global vaccine supply chain.
Segment Analysis: By End User
Human Use Segment in Vaccine Contract Manufacturing Market
The human use segment dominates the vaccine contract manufacturing market, commanding approximately 91% of the total market share in 2024. This substantial market share is attributed to the increasing demand for vaccines to treat various chronic and infectious diseases in humans, coupled with growing government initiatives and awareness programs promoting vaccination. The segment's leadership position is further strengthened by its impressive growth trajectory, expected to grow at around 11% from 2024 to 2029, making it the fastest-growing segment in the market. This growth is primarily driven by the rising global focus on preventive healthcare, increasing investments in vaccine development and manufacturing capabilities, and the expanding scope of vaccination programs worldwide. The segment's robust performance is also supported by technological advancements in vaccine production, stringent regulatory policies ensuring vaccine quality and safety, and the continuous emergence of new vaccine platforms and delivery systems.
Veterinary Segment in Vaccine Contract Manufacturing Market
The veterinary segment plays a crucial role in the vaccine contract manufacturing market by addressing the growing demand for animal vaccines across both livestock and companion animals. This segment's significance is underscored by the increasing awareness of animal health, rising pet ownership rates, and the growing importance of livestock vaccination in ensuring food security and preventing zoonotic diseases. The segment benefits from continuous technological advancements in veterinary vaccine development, expanding research activities in animal health, and the implementation of stringent regulations regarding animal vaccination. Furthermore, the rising adoption of preventive healthcare measures in veterinary medicine, coupled with the growing focus on reducing the use of antibiotics in livestock, has created new opportunities for veterinary vaccine manufacturers. The segment also sees substantial support from government initiatives promoting animal health and welfare, particularly in developing regions where livestock health is crucial for economic stability.
Vaccine Contract Manufacturing Market Geography Segment Analysis
Vaccine Contract Manufacturing Market in North America
The North American vaccine contract manufacturing market demonstrates robust growth driven by advanced technological infrastructure, a strong presence of major pharmaceutical companies, and a supportive regulatory environment. The United States, Canada, and Mexico form the key markets in this region, with each country contributing uniquely to the regional landscape. The region benefits from extensive research and development activities, established manufacturing facilities, and increasing partnerships between contract manufacturers and vaccine developers.
Vaccine Contract Manufacturing Market in the United States
The United States dominates the North American vaccine contract manufacturing landscape, holding approximately 87% market share in the region. The country's leadership position is strengthened by its advanced manufacturing capabilities, the presence of major contract manufacturing organizations, and substantial government support for vaccine development and production. The market is characterized by strategic collaborations between pharmaceutical companies and contract manufacturers, state-of-the-art manufacturing facilities, and continuous technological advancements in vaccine production processes.
Growth Dynamics in United States Vaccine Contract Manufacturing
The United States continues to demonstrate strong growth potential with an expected CAGR of approximately 11% during 2024-2029. This growth is driven by increasing investments in manufacturing infrastructure, rising demand for innovative vaccine platforms, and expanding contract manufacturing capabilities. The country's focus on developing next-generation vaccines, coupled with strong regulatory support and technological innovation, positions it as a key growth driver in the North American vaccine contract manufacturing market.
Vaccine Contract Manufacturing Market in Europe
The European vaccine contract manufacturing market showcases significant development with strong contributions from Germany, the United Kingdom, France, Italy, and Spain. The region benefits from well-established pharmaceutical infrastructure, stringent quality standards, and an increasing focus on innovative vaccine technologies. The market is characterized by strategic collaborations between contract manufacturers and vaccine developers, supported by favorable government policies and research initiatives.
Vaccine Contract Manufacturing Market in Germany
Germany leads the European vaccine contract manufacturing market, commanding approximately 23% market share in the region. The country's strong position is attributed to its advanced manufacturing capabilities, robust research and development infrastructure, and the presence of major contract manufacturing organizations. The German market is characterized by high-quality standards, technological innovation, and a strong focus on developing next-generation vaccine manufacturing capabilities.
Growth Dynamics in French Vaccine Contract Manufacturing
France emerges as the fastest-growing market in Europe with an anticipated CAGR of approximately 11% during 2024-2029. The country's growth is driven by increasing investments in vaccine manufacturing infrastructure, a rising focus on innovative vaccine technologies, and strong government support for the pharmaceutical sector. France's commitment to expanding its vaccine manufacturing capabilities, coupled with strategic partnerships and technological advancements, positions it as a key growth market in Europe.
Vaccine Contract Manufacturing Market in Asia-Pacific
The Asia-Pacific vaccine contract manufacturing market demonstrates dynamic growth potential with significant contributions from China, Japan, India, Australia, and South Korea. The region benefits from expanding manufacturing capabilities, increasing investments in pharmaceutical infrastructure, and a growing focus on vaccine development. The market is characterized by rising partnerships between local and international players, government support for vaccine manufacturing, and continuous technological advancements.
Vaccine Contract Manufacturing Market in China
China leads the Asia-Pacific vaccine contract manufacturing market, demonstrating a strong market presence through its extensive manufacturing infrastructure, large-scale production capabilities, and growing technological expertise. The country's dominance is supported by substantial government investments, the presence of major contract manufacturing organizations, and an increasing focus on quality standards in vaccine production.
Growth Dynamics in Chinese Vaccine Contract Manufacturing
China maintains its position as the fastest-growing market in the Asia-Pacific region, driven by the rapid expansion of manufacturing capabilities, increasing technological adoption, and strong government support for vaccine development. The market shows remarkable progress in adopting innovative manufacturing technologies, expanding production capacity, and strengthening quality control measures.
Vaccine Contract Manufacturing Market in Middle East & Africa
The Middle East & Africa vaccine contract manufacturing market demonstrates emerging potential with key contributions from GCC countries and South Africa. The region is witnessing increasing investments in pharmaceutical infrastructure, a growing focus on local manufacturing capabilities, and rising partnerships with international players. The GCC emerges as the largest market while South Africa shows the fastest growth potential, both driven by government initiatives to strengthen local vaccine manufacturing capabilities and an increasing focus on healthcare infrastructure development.
Vaccine Contract Manufacturing Market in South America
The South American vaccine contract manufacturing market shows promising development with Brazil and Argentina as key contributors. The region is characterized by increasing investments in manufacturing infrastructure, growing partnerships with international players, and a rising focus on local vaccine production capabilities. Brazil emerges as both the largest and fastest-growing market in the region, supported by strong government initiatives, expanding manufacturing capabilities, and an increasing focus on technological advancement in vaccine production.
Get Analysis on Important Geographic Markets
Download PDF
Vaccine Contract Manufacturing Industry Overview
Top Companies in Vaccine Contract Manufacturing Market
The vaccine contract manufacturing market features prominent players like Lonza Group AG, Catalent, Charles River Laboratories, ICON PLC, and Emergent BioSolutions leading the industry. These companies have demonstrated strong innovation capabilities through the integration of advanced technologies such as artificial intelligence, machine learning, and cloud-based platforms in their manufacturing processes. Strategic expansions through new facility establishments and modernization of existing infrastructure have been key trends, particularly focusing on modular bioprocessing units and single-use technologies. Companies are increasingly investing in specialized capabilities for mRNA-based vaccines and viral vectors while simultaneously strengthening their fill-finish operations. The market has witnessed significant collaboration activities, with major players forming strategic partnerships to enhance their manufacturing capabilities and geographic presence, particularly in emerging markets. Additionally, companies are focusing on developing end-to-end service capabilities, from preclinical development to commercial manufacturing, to provide comprehensive solutions to their clients.
Consolidated Market with Strong Regional Players
The vaccine contract manufacturing landscape exhibits a moderately consolidated structure, characterized by the presence of both global conglomerates and specialized regional players. Global leaders maintain their dominance through extensive manufacturing networks, technological superiority, and broad service portfolios, while regional specialists carve out niches through expertise in specific vaccine types or manufacturing processes. The market has witnessed significant merger and acquisition activities, particularly focused on expanding capabilities in emerging vaccine technologies and strengthening presence in high-growth markets. These strategic moves have been driven by the need to acquire specialized expertise, enhance manufacturing capacity, and establish stronger footholds in key geographic regions.
The competitive dynamics are further shaped by the increasing presence of Asian contract manufacturers, particularly from countries like South Korea and Japan, who are rapidly expanding their capabilities and global reach. Market consolidation has been particularly notable in specialized segments such as cell culture technology and fill-finish operations, where larger players have acquired smaller, technology-focused companies to enhance their service offerings. The industry has also seen the emergence of strategic partnerships between vaccine contract manufacturing companies and vaccine developers, creating long-term manufacturing agreements and risk-sharing models.
Innovation and Flexibility Drive Future Success
Success in the vaccine contract manufacturing market increasingly depends on companies' ability to adapt to rapidly evolving technologies and changing market demands. Incumbent players must focus on continuous technological upgrades, particularly in areas like automation and process control, while maintaining flexibility to handle different types of vaccines and manufacturing scales. Building strong quality management systems, developing expertise in regulatory compliance across multiple regions, and investing in specialized capabilities for next-generation vaccines are crucial strategies for maintaining market leadership. Companies also need to focus on developing sustainable manufacturing practices and establishing robust supply chain networks to ensure uninterrupted service delivery.
For emerging players and contenders, the path to success lies in identifying and developing expertise in specific niches within the vaccine manufacturing value chain. This includes focusing on particular vaccine types, specialized manufacturing processes, or specific geographic markets where they can build competitive advantages. The increasing adoption of modular manufacturing facilities and single-use technologies presents opportunities for newer players to enter the market with lower initial capital investments. Additionally, companies need to consider the impact of evolving regulations, particularly around quality standards and environmental sustainability, while also maintaining strong relationships with both vaccine developers and regulatory authorities to ensure long-term success in the market.
Vaccine Contract Manufacturing Market Leaders
-
Ajinomoto Bio-Pharma Services
-
Curia Global
-
Charles River Laboratories International Inc.
-
Emergent BioSolutions Inc.
-
IDT Biologika GmbH
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Vaccine Contract Manufacturing Market News
- August 2022: Moderna inked an agreement with the Canadian government to construct a messenger RNA vaccine manufacturing factory in an undetermined location in Canada. According to the biotech firm, the partnership will give Canadians access to mRNA vaccines made in Canada against respiratory viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus.
- June 2022: Merck and Agilent Technologies collaborated with each other to advance process analytical technologies for downstream processing and overcome the gaps within downstream processing.
Vaccine Contract Manufacturing Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Advancements in Technology and Cost Benefits in Infrastructure and Operational Benefits
- 4.2.2 Increase in Initiatives Favoring Vaccinations
- 4.2.3 Favorable Patient Demographics and Growing Vaccinations of Newborns and Children
-
4.3 Market Restraints
- 4.3.1 Rising High Costs of Vaccines
- 4.3.2 Lack of Storage Infrastructure and Limitations Associated with Supply Chain
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
5.1 By Vaccine Type
- 5.1.1 Inactivated Vaccines
- 5.1.2 Live-attenuated Vaccines
- 5.1.3 RNA Vaccines
- 5.1.4 Subunit Vaccines
- 5.1.5 Toxoid-based Vaccines
-
5.2 By Process
- 5.2.1 Downstream
- 5.2.1.1 Analytical and QC Studies
- 5.2.1.2 Fill and Finish
- 5.2.1.3 Packaging
- 5.2.1.4 Other Downstream Processes
- 5.2.2 Upstream
- 5.2.2.1 Bacterial Expression Systems
- 5.2.2.2 Baculovirus/Insect Expression Systems
- 5.2.2.3 Mammalian Expression Systems
- 5.2.2.4 Yeast Expression Systems
- 5.2.2.5 Other Upstream Processes
-
5.3 By Scale of Operations
- 5.3.1 Preclinical
- 5.3.2 Clinical
- 5.3.3 Commercial
-
5.4 By End Use
- 5.4.1 Human Use
- 5.4.2 Veterinary
-
5.5 Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 Australia
- 5.5.3.5 South Korea
- 5.5.3.6 Rest of Asia-Pacific
- 5.5.4 Middle East and Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle East and Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Ajinomoto Bio-Pharma Services
- 6.1.2 Curia Global
- 6.1.3 Catalent
- 6.1.4 Charles River Laboratories International Inc.
- 6.1.5 CJ CheilJedang Corporation (Batavia Biosciences)
- 6.1.6 Emergent BioSolutions Inc.
- 6.1.7 Fujifilm Holdings Corporation
- 6.1.8 ICON PLC
- 6.1.9 IDT Biologika GmbH
- 6.1.10 Lonza Group AG
- 6.1.11 Recipharm AB
- 6.1.12 Gedeon Richter (Richter-Helm BioLogics)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now
Vaccine Contract Manufacturing Industry Segmentation
As per the scope of this report, vaccine contract manufacturing is the outsourcing of vaccine production on a large scale to manufacturing units, such as contract manufacturing organizations.
The vaccine contract manufacturing market is segmented by vaccine type (inactivated vaccines, live-attenuated vaccines, RNA vaccines, subunit vaccines, and toxoid-based vaccines), process (downstream (analytical and QC studies, fill and finish, packaging, other downstream processes) and upstream (bacterial expression systems, baculovirus/insect expression systems, mammalian expression systems, yeast expression systems, other upstream processes)), the scale of operations (preclinical, clinical, and commercial), end use (human use and veterinary), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values (in USD million) for the above-mentioned segments.
| By Vaccine Type | Inactivated Vaccines | ||
| Live-attenuated Vaccines | |||
| RNA Vaccines | |||
| Subunit Vaccines | |||
| Toxoid-based Vaccines | |||
| By Process | Downstream | Analytical and QC Studies | |
| Fill and Finish | |||
| Packaging | |||
| Other Downstream Processes | |||
| Upstream | Bacterial Expression Systems | ||
| Baculovirus/Insect Expression Systems | |||
| Mammalian Expression Systems | |||
| Yeast Expression Systems | |||
| Other Upstream Processes | |||
| By Scale of Operations | Preclinical | ||
| Clinical | |||
| Commercial | |||
| By End Use | Human Use | ||
| Veterinary | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Vaccine Contract Manufacturing Market Research FAQs
How big is the Vaccine Contract Manufacturing Market?
The Vaccine Contract Manufacturing Market size is expected to reach USD 3.90 billion in 2025 and grow at a CAGR of 11.18% to reach USD 6.63 billion by 2030.
What is the current Vaccine Contract Manufacturing Market size?
In 2025, the Vaccine Contract Manufacturing Market size is expected to reach USD 3.90 billion.
Who are the key players in Vaccine Contract Manufacturing Market?
Ajinomoto Bio-Pharma Services, Curia Global, Charles River Laboratories International Inc., Emergent BioSolutions Inc. and IDT Biologika GmbH are the major companies operating in the Vaccine Contract Manufacturing Market.
Which is the fastest growing region in Vaccine Contract Manufacturing Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Vaccine Contract Manufacturing Market?
In 2025, the North America accounts for the largest market share in Vaccine Contract Manufacturing Market.
What years does this Vaccine Contract Manufacturing Market cover, and what was the market size in 2024?
In 2024, the Vaccine Contract Manufacturing Market size was estimated at USD 3.46 billion. The report covers the Vaccine Contract Manufacturing Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Vaccine Contract Manufacturing Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Vaccine Contract Manufacturing Market Research
Mordor Intelligence provides a comprehensive analysis of the vaccine contract manufacturing market, drawing on our extensive experience in pharmaceutical industry research. Our expert analysts offer detailed insights into viral vaccine manufacturing processes and mRNA vaccine manufacturing technologies. They also explore the evolving landscape of vaccine development and manufacturing. The report examines key players in the vaccine contract manufacturing industry, including leading vaccine CMO and vaccine CDMO organizations. It offers strategic perspectives on current operations and future developments.
This detailed industry analysis benefits stakeholders by providing actionable insights into contract vaccine manufacturing trends. There is a particular focus on vaccine bulk manufacturing processes and vaccine fill finish operations. The report explores various vaccine testing services methodologies and evaluates prominent vaccine contract manufacturing companies. It delivers comprehensive data in an easy-to-read report PDF format available for download. Our analysis covers both traditional and emerging manufacturing technologies, ensuring stakeholders receive the most current and relevant information for strategic decision-making.
